CN106086078B - 一种car‑t细胞毒性指示载体 - Google Patents
一种car‑t细胞毒性指示载体 Download PDFInfo
- Publication number
- CN106086078B CN106086078B CN201610537806.3A CN201610537806A CN106086078B CN 106086078 B CN106086078 B CN 106086078B CN 201610537806 A CN201610537806 A CN 201610537806A CN 106086078 B CN106086078 B CN 106086078B
- Authority
- CN
- China
- Prior art keywords
- car
- cell
- luciferase
- supernatant
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract description 7
- 230000007541 cellular toxicity Effects 0.000 title abstract description 6
- 210000004027 cell Anatomy 0.000 claims abstract description 97
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 42
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 42
- 239000005089 Luciferase Substances 0.000 claims abstract description 35
- 108060001084 Luciferase Proteins 0.000 claims abstract description 25
- 239000006228 supernatant Substances 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 108091007433 antigens Proteins 0.000 claims abstract description 15
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 241000700605 Viruses Species 0.000 claims abstract description 12
- 238000001556 precipitation Methods 0.000 claims abstract description 12
- 230000006037 cell lysis Effects 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 241000713666 Lentivirus Species 0.000 claims abstract description 5
- 238000001514 detection method Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 206010061217 Infestation Diseases 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 238000009169 immunotherapy Methods 0.000 abstract description 3
- 238000005336 cracking Methods 0.000 abstract description 2
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000969 carrier Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 5
- 238000011357 CAR T-cell therapy Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- XQNRANMFRPCFFW-GCJQMDKQSA-N Ala-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C)N)O XQNRANMFRPCFFW-GCJQMDKQSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- QQLBPVKLJBAXBS-FXQIFTODSA-N Glu-Glu-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QQLBPVKLJBAXBS-FXQIFTODSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- ZGUMORRUBUCXEH-AVGNSLFASA-N Leu-Lys-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZGUMORRUBUCXEH-AVGNSLFASA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 206010041047 Slow virus infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010039538 alanyl-glycyl-aspartyl-valine Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
指示细胞数目D | D10 | D100 | D1000 | D10000 | D100000 |
荧光素酶活力值 | 681 | 8554 | 85870 | 975411 | 31931660 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610537806.3A CN106086078B (zh) | 2016-07-08 | 2016-07-08 | 一种car‑t细胞毒性指示载体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610537806.3A CN106086078B (zh) | 2016-07-08 | 2016-07-08 | 一种car‑t细胞毒性指示载体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106086078A CN106086078A (zh) | 2016-11-09 |
CN106086078B true CN106086078B (zh) | 2017-12-22 |
Family
ID=57212782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610537806.3A Active CN106086078B (zh) | 2016-07-08 | 2016-07-08 | 一种car‑t细胞毒性指示载体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106086078B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106822184A (zh) * | 2016-12-15 | 2017-06-13 | 梁爱斌 | 多靶点联合的car‑t细胞制剂与制备方法 |
WO2019157691A1 (zh) | 2018-02-14 | 2019-08-22 | 宜明细胞生物科技有限公司 | 一种重组嵌合抗原受体基因及其应用 |
CN108753916A (zh) * | 2018-06-04 | 2018-11-06 | 杭州启澜生物医学技术有限公司 | 一种快速评估car-t细胞体外杀伤效率的方法 |
CN110129370B (zh) * | 2019-05-06 | 2021-07-20 | 山东昂科诺生物科技有限公司 | 一种car-t毒性指示细胞的快速构建方法 |
CN111358956B (zh) * | 2020-03-25 | 2021-07-09 | 南京鼓楼医院 | 一种纳米开关分子及其控制激活的实体瘤靶向性car-t细胞 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104910279A (zh) * | 2015-06-05 | 2015-09-16 | 重庆倍思益生物科技有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
CN105418765A (zh) * | 2014-08-26 | 2016-03-23 | 西比曼生物科技(上海)有限公司 | Cd19靶向性的嵌合抗原受体和nkt细胞及其制法和应用 |
CN105602992A (zh) * | 2016-03-17 | 2016-05-25 | 上海优卡迪生物医药科技有限公司 | 一种基于复制缺陷性重组慢病毒的car-t转基因载体及其构建方法和应用 |
-
2016
- 2016-07-08 CN CN201610537806.3A patent/CN106086078B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418765A (zh) * | 2014-08-26 | 2016-03-23 | 西比曼生物科技(上海)有限公司 | Cd19靶向性的嵌合抗原受体和nkt细胞及其制法和应用 |
CN104910279A (zh) * | 2015-06-05 | 2015-09-16 | 重庆倍思益生物科技有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
CN105602992A (zh) * | 2016-03-17 | 2016-05-25 | 上海优卡迪生物医药科技有限公司 | 一种基于复制缺陷性重组慢病毒的car-t转基因载体及其构建方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106086078A (zh) | 2016-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106086078B (zh) | 一种car‑t细胞毒性指示载体 | |
Zhang et al. | Optimized DNA electroporation for primary human T cell engineering | |
Good et al. | An NK-like CAR T cell transition in CAR T cell dysfunction | |
Watanabe et al. | Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses | |
De Nola et al. | The crowded crosstalk between cancer cells and stromal microenvironment in gynecological malignancies: biological pathways and therapeutic implication | |
Choi et al. | Signaling by the Epstein–Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses | |
Rosenbaum et al. | Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response | |
Gujar et al. | Oncolytic virus-initiated protective immunity against prostate cancer | |
Chandramohan et al. | Validation of an immunohistochemistry assay for detection of CD155, the poliovirus receptor, in malignant gliomas | |
CN106636090B (zh) | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 | |
CN109485721A (zh) | 一种获得肿瘤特异性t细胞受体的方法 | |
CN107286247B (zh) | 含抗间皮素单链抗体的嵌合抗原受体修饰的树突状细胞及其用途 | |
CN105296431B (zh) | 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途 | |
Johnson et al. | Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity | |
Wilk et al. | Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy | |
CN110272493A (zh) | 靶向cd19的特异性嵌合抗原受体t细胞及其制备方法和临床应用 | |
Krump et al. | From Merkel cell polyomavirus infection to Merkel cell carcinoma oncogenesis | |
CN109797171A (zh) | 经修饰的t细胞、其制备方法及用途 | |
Clements et al. | Newly recruited CD11b+, GR-1+, Ly6Chigh myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus | |
CN109111525A (zh) | 一种hla-g嵌合抗原受体、编码序列和表达载体以及应用 | |
CN105802909A (zh) | 具有her2特异性tcr的t细胞制备物及其用途 | |
CN110423767A (zh) | 表达可溶性pd-1的嵌合抗原受体car基因及应用 | |
CN108822216B (zh) | 携带截短或未截短的自然细胞毒性受体信号结构的嵌合抗原受体及其应用 | |
CN107475275A (zh) | 嵌合抗原受体及其表达基因、双抗原调节的嵌合抗原受体修饰的t细胞及其应用 | |
WO2022012198A1 (zh) | 一种用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Floor 1, 125, Building 3, 538, Yongfeng Tun, Haidian District, Beijing, 100000 Patentee after: Yiming (Beijing) Cell Biotechnology Co.,Ltd. Address before: Tian Tong Yuan, Changping District, Beijing Patentee before: IMMUNE CELL BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191115 Address after: Room 206, building 17, Life Science City, pharmaceutical Valley Industrial Park, 1777 Dazheng Road, East District, high tech Zone, Jinan City, Shandong Province 250000 Patentee after: Jinan Yiming Medical Technology Co.,Ltd. Address before: 100000 1 floor 125, 3 tower 538, Yongfeng Tun, Haidian District, Beijing. Patentee before: Yiming (Beijing) Cell Biotechnology Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: Room 206, building 17, Life Science City, pharmaceutical Valley Industrial Park, 1777 Dazheng Road, East Street, high tech Zone, Jinan City, Shandong Province Patentee after: Yiming (Jinan) Biotechnology Co.,Ltd. Country or region after: China Address before: Room 206, building 17, Life Science City, pharmaceutical Valley Industrial Park, 1777 Dazheng Road, East Street, high tech Zone, Jinan City, Shandong Province Patentee before: Jinan Yiming Medical Technology Co.,Ltd. Country or region before: China |